MOLECULAR THERAPEUTICS RESEARCH PROGRAM

分子治疗计划（MT）的目标是促进思想交流，合作， 合作导致翻译的基础研究集中在识别和发展的小说 将治疗学应用于临床，并利用基础研究来回答与以下方面相关的临床问题： 改善癌症的治疗。MT计划提供了一个论坛，讨论和促进 新的发展，在目标识别，药物发现，和药物作用机制，并为翻译 将这些方法用于新的相关性和治疗性临床试验。目前，该项目有27个 来自7个部门的成员和820万美元的总资金，其中近400万美元（61%）来自 NCI近5年的论文产出量超过240篇，其中16%为项目内论文，26%为项目间论文 合作出版物。18名项目教师参加了项目内，18名参加了项目间 合作，提供了一个高度互动的研究计划的有力证据。最近 计划的重点包括脂肪酸合成酶途径作为一个独立的作用的证据， 乳腺癌进展的标志物，并认识到它可以靶向抑制肿瘤生长。 正在研究的其他分子靶点包括Hedgehog信号通路中的蛋白质， 在非小细胞肺癌中经常被激活。新的药物，如新的蛋白酶体抑制剂， 抗凋亡蛋白Mcl-1和Bcl-2的抑制因子正在研究中，期望 将这些药物带到莫里斯·科顿癌症中心进行临床试验。开发的新治疗策略 已经转化为I期临床试验的MT计划包括顺铂加 Chk 1抑制剂UCN-01。在这项研究中，连续的肿瘤活检被用来监测肿瘤中的生物活性。 组织.其他研究人员开发了新的技术和补充方法来定义 预测标志物和治疗策略，MT计划的一个重要目标是测试这些 在NCCC的相关和治疗性临床试验的想法。值得特别注意的还有一系列 在新辅助治疗环境中使用放化疗治疗胰腺癌的I期和II期临床试验 在这种高度侵袭性的疾病中确定了一种有前途的治疗方法，并证明了该计划的 对癌症患者疾病结局的影响。

The goal of the Molecular Therapeutics Program (MT) is to foster the exchange of ideas, cooperation, and collaboration leading to translation of basic research focused on the identification and development of novel therapeutics into clinical applications, and to use basic research to answer clinical questions related to improving the treatment of cancer. The MT Program provides a forum for discussion and advancement of new developments in target identification, drug discovery, and mechanisms of drug action, and for translating these approaches into novel correlative and therapeutic clinical trials. The Program currently has 27 members from 7 departments and $8.2 millon in total funding, of which almost $4 million (61%) is from the NCI. The productivity over the past 5 years exceeds 240 papers, including 16% intra-program and 26% interprogram collaborative publications. Eighteen Program faculty participated in intra-program and 18 in interprogram collaborations, providing strong evidence of a highly interactive research program. Recent programmatic highlights include evidence for the role of the fatty acid synthase pathway as an independent marker of breast cancer progression, and the recognition that it can be targeted to suppress tumor growth. Other molecular targets under investigation include proteins in the Hedgehog signaling pathway, which is frequently activated in non-small cell lung cancer. New agents such as novel proteasome inhibitors and suppressors of the anti-apoptotic proteins Mcl-1 and Bcl-2 are under investigation, with the expectation of bringing these drugs to clinical trial at Morris Cotton Cancer Center. Novel treatment strategies developed in the MT Program that have been translated into Phase I clinical trials include the combination of cisplatin plus the Chk1 inhibitor UCN-01. In is study serial tumor biopsies were used to monitor biological activity in tumor tissue. Other investigators have developed novel technologies and complementary approaches to define predictive markers and therapeutic strategies, and an important goal of the MT Program is to test these ideas in correlative and therapeutic clinical trials at the NCCC. Also worthy of particular notice is a series of Phase I and II clinical trials in pancreatic cancer using chemoradiation in the neoadjuvant setting that has identified a promising treatment approach in this highly aggressive disease and demonstrates the Program's impact on disease outcome in cancer patients.